ORIC updates registrational plans for lead drugs, extends cash runway into 2027

Oric Pharmaceuticals, Inc.

ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.
ORIC-114 registrational focus on 1L NSCLC with Phase 3 trials planned 2026; 2L/2L+ registration deprioritized.
Comprehensive NSCLC data update expected 2H 2025 including 1L EGFR exon 20 and atypical cohorts.
Cash, cash equivalents and investments totaled $256M as of Dec 31, 2024; projected runway extended into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.